Table 3.
SARS-CoV-2 vaccines in development.
| Name | Developer(s) | Vaccine Type | Trial Phase |
|---|---|---|---|
| * mRNA 1273 | Moderna and NIAID | mRNA vaccine | Phase 3 |
| * ChAdOx1 | University of Oxford and AstraZeneca | Non-replicating viral vector | Phase 2b/3 |
| CoronaVacc | Sinovac | Inactivated vaccine | Phase 3 |
| N/A | Beijing Institute of Biological Products and Sinopharm | Inactivated vaccine | Phase 1/2 |
| N/A | Wuhan Institute of Biological Products and Sinopharm | Inactivated vaccine | Phase 1/2 |
| N/A | Institute of Medical Biology, Chinese Academy of Medical Sciences | Inactivated vaccine | Phase 1 |
| N/A | Novavax | Subunit vaccine | Phase 1/2 |
| Ad5-nCoV | CanSino Biological Incorporation, Beijing Institute of Biotechnology and Canadian Center for Vaccinology | Non-replicating viral vector (adenovirus type 5) | Phase 1 and phase 2 |
| N/A | Shenzhen Geno-Immune Medical Institute | Non-replicating viral vector | Procedure 1: Phase 1/2Procedure 2: Phase 1 |
| INO-4800 | Inovio Pharmaceuticals | DNA vaccine | Phase 1 |
| N/A | Symvivo | DNA vaccine | Phase 1 |
| * BNT162 | BioNTech, Pfizer, and Fosun Pharma | RNA vaccine | Phase 1/2 |
| * COVAXIN | Bharat Biotech | Inactivated vaccine | Phase 3 |
Currently, mRNA 1273 and COVAXIN are in a phase 3 clinical trial as an mRNA vaccine and inactivated vaccine, respectively. ChAdOx1 is a non-replicating viral vector that is in phase 2b/3. CoronaVacc is an inactivated vaccine in a phase 3 clinical trial. In addition, there are three other inactivated vaccines in phase 1 or phase 1/2 clinical trials. There are two non-replicating viral vector vaccines, one of which is Ad4-nCoV, which are in phase 1 and phase 2 clinical trials. Two DNA vaccines, including INO-4800, are in phase 1 clinical trials. BNT162 is an RNA vaccine in a phase 1/2 clinical trial. * Approved for emergency use.